Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
March 31 2011 - 3:00AM
Business Wire
Inhibitex, Inc. (NASDAQ: INHX) announced today the presentation
of data from its single ascending dose Phase 1a study of INX-189 in
healthy volunteers. The poster presentation will be presented by
various scientists from the Company at the 46th European
Association for the study of the Liver in Berlin, Germany. The
abstract can be viewed at the EASL website at www.easl.eu.
The following poster will be presented during the Viral
Hepatitis C: Clinical (Therapy) Poster Session, today, March 31,
2011, from 9:00 am - 6:00 pm CEST.
- ID #460; Barry et al., “A STUDY OF THE
SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF
INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY
SUBJECTS"
The poster will be available in the INX-189 section of the
Inhibitex website.
About Inhibitex
Inhibitex, Inc., a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s pipeline includes FV-100, which is in Phase
II clinical development for the treatment of shingles, and INX-189,
a nucleotide polymerase inhibitor in development for the treatment
of chronic hepatitis C infections. The Company also has additional
HCV nucleotide polymerase inhibitors in preclinical development and
has licensed the use of its proprietary MSCRAMM® protein platform
to Pfizer for the development of staphylococcal vaccines. For
additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024